CN109884314B - Indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof - Google Patents
Indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof Download PDFInfo
- Publication number
- CN109884314B CN109884314B CN201910140122.3A CN201910140122A CN109884314B CN 109884314 B CN109884314 B CN 109884314B CN 201910140122 A CN201910140122 A CN 201910140122A CN 109884314 B CN109884314 B CN 109884314B
- Authority
- CN
- China
- Prior art keywords
- solution
- protein
- detection method
- coating
- elisa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002965 ELISA Methods 0.000 title claims abstract description 67
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 title claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 45
- 238000001514 detection method Methods 0.000 title claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 41
- 239000011248 coating agent Substances 0.000 claims abstract description 51
- 238000000576 coating method Methods 0.000 claims abstract description 51
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 41
- 238000005406 washing Methods 0.000 claims description 30
- 238000010790 dilution Methods 0.000 claims description 17
- 239000012895 dilution Substances 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 15
- 238000007789 sealing Methods 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 241000283707 Capra Species 0.000 claims description 9
- 230000035484 reaction time Effects 0.000 claims description 9
- 230000000903 blocking effect Effects 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000012089 stop solution Substances 0.000 claims description 8
- 238000011161 development Methods 0.000 claims description 7
- 235000020183 skimmed milk Nutrition 0.000 claims description 7
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 6
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000009385 viral infection Effects 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 238000005457 optimization Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 102100031673 Corneodesmosin Human genes 0.000 description 5
- 101710139375 Corneodesmosin Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000282887 Suidae Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 2
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 241000202347 Porcine circovirus Species 0.000 description 2
- 241001361508 Porcine deltacoronavirus Species 0.000 description 2
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 238000011999 immunoperoxidase monolayer assay Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 1
- SFNFGFDRYJKZKN-XQXXSGGOSA-N Ala-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O SFNFGFDRYJKZKN-XQXXSGGOSA-N 0.000 description 1
- ZDYNWWQXFRUOEO-XDTLVQLUSA-N Ala-Gln-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDYNWWQXFRUOEO-XDTLVQLUSA-N 0.000 description 1
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 1
- JDIQCVUDDFENPU-ZKWXMUAHSA-N Ala-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CNC=N1 JDIQCVUDDFENPU-ZKWXMUAHSA-N 0.000 description 1
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 1
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- MLNSNVLOEIYJIU-ZUDIRPEPSA-N Ala-Leu-Thr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MLNSNVLOEIYJIU-ZUDIRPEPSA-N 0.000 description 1
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 1
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 1
- DTBPLQNKYCYUOM-JYJNAYRXSA-N Arg-Met-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DTBPLQNKYCYUOM-JYJNAYRXSA-N 0.000 description 1
- JPAWCMXVNZPJLO-IHRRRGAJSA-N Arg-Ser-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JPAWCMXVNZPJLO-IHRRRGAJSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 1
- IICZCLFBILYRCU-WHFBIAKZSA-N Asn-Gly-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IICZCLFBILYRCU-WHFBIAKZSA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 1
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 1
- AYOAHKWVQLNPDM-HJGDQZAQSA-N Asn-Lys-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AYOAHKWVQLNPDM-HJGDQZAQSA-N 0.000 description 1
- ZNYKKCADEQAZKA-FXQIFTODSA-N Asn-Ser-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O ZNYKKCADEQAZKA-FXQIFTODSA-N 0.000 description 1
- HRGGPWBIMIQANI-GUBZILKMSA-N Asp-Gln-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HRGGPWBIMIQANI-GUBZILKMSA-N 0.000 description 1
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 1
- VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- 241000534000 Berula erecta Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YFXFOZPXVFPBDH-VZFHVOOUSA-N Cys-Ala-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CS)C(O)=O YFXFOZPXVFPBDH-VZFHVOOUSA-N 0.000 description 1
- MXZYQNJCBVJHSR-KATARQTJSA-N Cys-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)O MXZYQNJCBVJHSR-KATARQTJSA-N 0.000 description 1
- KVCJEMHFLGVINV-ZLUOBGJFSA-N Cys-Ser-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KVCJEMHFLGVINV-ZLUOBGJFSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- VSLCIGXQLCYQTD-NPJQDHAYSA-N Dynorphin B (10-13) Chemical compound NCCCC[C@@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H]([C@H](C)O)C(O)=O VSLCIGXQLCYQTD-NPJQDHAYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- LKUWAWGNJYJODH-KBIXCLLPSA-N Gln-Ala-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LKUWAWGNJYJODH-KBIXCLLPSA-N 0.000 description 1
- DLOHWQXXGMEZDW-CIUDSAMLSA-N Gln-Arg-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DLOHWQXXGMEZDW-CIUDSAMLSA-N 0.000 description 1
- JESJDAAGXULQOP-CIUDSAMLSA-N Gln-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N JESJDAAGXULQOP-CIUDSAMLSA-N 0.000 description 1
- MQANCSUBSBJNLU-KKUMJFAQSA-N Gln-Arg-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQANCSUBSBJNLU-KKUMJFAQSA-N 0.000 description 1
- LLVXTGUTDYMJLY-GUBZILKMSA-N Gln-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)N LLVXTGUTDYMJLY-GUBZILKMSA-N 0.000 description 1
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 1
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 description 1
- FKGNJUCQKXQNRA-NRPADANISA-N Glu-Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O FKGNJUCQKXQNRA-NRPADANISA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 1
- TWYFJOHWGCCRIR-DCAQKATOSA-N Glu-Pro-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYFJOHWGCCRIR-DCAQKATOSA-N 0.000 description 1
- GTFYQOVVVJASOA-ACZMJKKPSA-N Glu-Ser-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N GTFYQOVVVJASOA-ACZMJKKPSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- PMSDOVISAARGAV-FHWLQOOXSA-N Glu-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PMSDOVISAARGAV-FHWLQOOXSA-N 0.000 description 1
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
- WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 1
- JUBDONGMHASUCN-IUCAKERBSA-N Gly-Glu-His Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O JUBDONGMHASUCN-IUCAKERBSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 1
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 1
- QVDGHDFFYHKJPN-QWRGUYRKSA-N Gly-Phe-Cys Chemical compound NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O QVDGHDFFYHKJPN-QWRGUYRKSA-N 0.000 description 1
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 1
- XJQDHFMUUBRCGA-KKUMJFAQSA-N His-Asn-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XJQDHFMUUBRCGA-KKUMJFAQSA-N 0.000 description 1
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 description 1
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 1
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 1
- LLZLRXBTOOFODM-QSFUFRPTSA-N Ile-Asp-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N LLZLRXBTOOFODM-QSFUFRPTSA-N 0.000 description 1
- KIMHKBDJQQYLHU-PEFMBERDSA-N Ile-Glu-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KIMHKBDJQQYLHU-PEFMBERDSA-N 0.000 description 1
- SPQWWEZBHXHUJN-KBIXCLLPSA-N Ile-Glu-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O SPQWWEZBHXHUJN-KBIXCLLPSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 1
- FGBRXCZYVRFNKQ-MXAVVETBSA-N Ile-Phe-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N FGBRXCZYVRFNKQ-MXAVVETBSA-N 0.000 description 1
- FXJLRZFMKGHYJP-CFMVVWHZSA-N Ile-Tyr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FXJLRZFMKGHYJP-CFMVVWHZSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 1
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 1
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 1
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 1
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 1
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 1
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- PNHRPOWKRRJATF-IHRRRGAJSA-N Met-Tyr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 PNHRPOWKRRJATF-IHRRRGAJSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QCHNRQQVLJYDSI-DLOVCJGASA-N Phe-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 QCHNRQQVLJYDSI-DLOVCJGASA-N 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- KUSYCSMTTHSZOA-DZKIICNBSA-N Phe-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N KUSYCSMTTHSZOA-DZKIICNBSA-N 0.000 description 1
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 102000044437 S1 domains Human genes 0.000 description 1
- 108700036684 S1 domains Proteins 0.000 description 1
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 1
- IDQFQFVEWMWRQQ-DLOVCJGASA-N Ser-Ala-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IDQFQFVEWMWRQQ-DLOVCJGASA-N 0.000 description 1
- JJKSSJVYOVRJMZ-FXQIFTODSA-N Ser-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)CN=C(N)N JJKSSJVYOVRJMZ-FXQIFTODSA-N 0.000 description 1
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 1
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- OWCVUSJMEBGMOK-YUMQZZPRSA-N Ser-Lys-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O OWCVUSJMEBGMOK-YUMQZZPRSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- PZVGOVRNGKEFCB-KKHAAJSZSA-N Thr-Asn-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N)O PZVGOVRNGKEFCB-KKHAAJSZSA-N 0.000 description 1
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 1
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- XMNDQSYABVWZRK-BZSNNMDCSA-N Tyr-Asn-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XMNDQSYABVWZRK-BZSNNMDCSA-N 0.000 description 1
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 1
- WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 1
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 1
- AEOFMCAKYIQQFY-YDHLFZDLSA-N Tyr-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AEOFMCAKYIQQFY-YDHLFZDLSA-N 0.000 description 1
- BQASAMYRHNCKQE-IHRRRGAJSA-N Tyr-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N BQASAMYRHNCKQE-IHRRRGAJSA-N 0.000 description 1
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 1
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 1
- CFSSLXZJEMERJY-NRPADANISA-N Val-Gln-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CFSSLXZJEMERJY-NRPADANISA-N 0.000 description 1
- QHFQQRKNGCXTHL-AUTRQRHGSA-N Val-Gln-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QHFQQRKNGCXTHL-AUTRQRHGSA-N 0.000 description 1
- ZEVNVXYRZRIRCH-GVXVVHGQSA-N Val-Gln-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N ZEVNVXYRZRIRCH-GVXVVHGQSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- LTTQCQRTSHJPPL-ZKWXMUAHSA-N Val-Ser-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N LTTQCQRTSHJPPL-ZKWXMUAHSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses an indirect ELISA antibody detection kit for porcine epidemic diarrhea virus S2 protein, which comprises a coated ELISA plate, wherein the coated ELISA plate takes recombinant S2 protein as a coating antigen. Therefore, a corresponding ELISA detection method is established and is clinically applied, and a diagnostic tool with practical value is provided for detecting the PEDV antibody. The method for identifying the antibody generated by the porcine epidemic diarrhea virus infection can be established, has higher specificity and sensitivity, is simple to operate, short in time consumption and low in cost, can be used for large-scale detection, and has important significance for prevention, control and purification of the porcine epidemic diarrhea virus infection.
Description
Technical Field
The invention belongs to the technical field of porcine epidemic diarrhea virus, and particularly relates to an indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and a kit thereof.
Background
Porcine Epidemic Diarrhea (PED) is a highly-contact acute infectious disease caused by Porcine Epidemic Diarrhea Virus (PEDV), and mainly transmitted by a fecal oral route, infected pigs have symptoms of vomiting, watery diarrhea, dehydration and the like, piglets die from dehydration and acidosis, and the death rate is higher when the pigs are younger. Porcine epidemic diarrhea was first reported in the uk and belgium in the 70 s of the 20 th century, and then the occurrence of this disease was also reported in succession in a number of asian countries including china, philippines, korea, etc. Since 2010, large-scale outbreaks of PED are continuously reported in a plurality of provinces or regions in China, and a large-scale pig farm immunized with epidemic diarrhea vaccines also outbreaks of PED, so that newborn piglets die in a large amount and are disastrous. PED was also first outbreak in 2013 in America, and later it was confirmed that the virus variation caused the pandemic of PEDV in countries and regions in America, causing enormous economic loss to the pig industry.
Porcine Epidemic Diarrhea Virus (PEDV) is a single-stranded positive strand RNA virus and belongs to the genus coronavirus of the family coronaviridae, the order capsuloviridae, on a genetic classification. The PEDV genome encodes 4 major structural proteins in total, namely nucleocapsid protein (N), envelope protein (E), membrane protein (M) and spike protein (S). The S protein is located on the surface of the virion, consists of 1383 amino acids and is divided into two functional regions, namely S1 (1-789 aa) and S2 (790-1383 aa), and plays a key role in mediating the virion to enter cells and inducing an organism to generate neutralizing antibodies. After 2010 in China, PEDV epidemic strains separated from diseased pig intestines or excrement are mainly variant strains, and compared with a classical vaccine strain CV777, the PEDV epidemic strains have a lot of variations on an S gene, so that virus toxicity is enhanced or an immune escape mechanism of the virus is changed, and the PED is promoted to be greatly outbreak in China. Sun et al report that the protein 636-789 aa of S1 is a highly conserved region capable of inducing the body to produce neutralizing antibodies. Sundonbo identified the S1 region of the S protein as having 5 linear epitope regions and 1 neutralizing epitope using a filamentous phage display system. The pronucleus such as guirui expresses PEDV partial S1 protein (60-845bp), and the recombinant protein is expressed and has good reactogenicity, and can be identified by rabbit PEDV polyclonal antiserum. The studies described above mainly address the function of the PEDV S protein S1 domain, while there are few studies on the function of the PEDV S protein S2 domain, such as antigenicity.
The detection method of the porcine epidemic diarrhea antibody mainly comprises an indirect immunofluorescence assay (IFA), a virus neutralization assay (VN), an immunoperoxidase monolayer assay (IPMA) and an enzyme-linked immunosorbent assay (ELISA). Compared with other detection methods, the ELISA method is simple, convenient and sensitive, and is suitable for detection and evaluation of batch samples. Scholars at home and abroad establish an ELISA antibody detection method aiming at the PEDV holovirus and based on the recombinant N protein and the S1 protein. The detection method of the PEDV indirect ELISA antibody is established by taking prokaryotic expression recombinant N protein as a detection antigen, optimizing ELISA reaction conditions and the like. Gerber and the like establish an indirect ELISA detection method of an S1 protein antibody based on eukaryotic expression PEDV S1 recombinant protein, and have good reaction on IgG and IgA; the recombinant PEDV partial spike protein is used as a detection antigen, an indirect ELISA antibody detection method based on PEDV S1 protein is established, and the method is used for detecting PEDV antibodies in sow serum, colostrum and serum of piglets of different ages on the day of delivery of sows immunized with PED inactivated vaccines 4 weeks before delivery. However, no indirect ELISA antibody detection method established based on the PEDV S2 recombinant protein is reported at present.
Disclosure of Invention
The invention aims to solve the technical problem of providing a swine epidemic diarrhea virus S2 protein indirect ELISA antibody detection method and a kit thereof.
In order to solve the technical problem, the invention adopts the following technical scheme:
the indirect ELISA antibody detection kit for the porcine epidemic diarrhea virus S2 protein comprises a coated ELISA plate, wherein the coated ELISA plate takes recombinant S2 protein as a coating antigen.
The recombinant S2 protein is encoded by a gene base sequence of a sequence table SEQ ID No.1 or has an amino acid sequence of SEQ ID No. 2.
The ELISA detection kit also comprises negativesSerum, positive serum, goat anti-pig IgG antibody marked by HRP, washing liquid, diluent, coating liquid, confining liquid, substrate liquid and stop solution; the washing solution is PBS + 0.05% Tween-20; the diluent is PBS + 2% skimmed milk powder + 0.05% Tween-20; the coating liquid is 0.05M PH9.6Na2CO3-NaHCO3A buffer solution; the substrate solution is a single-component TMB substrate color development solution; the confining liquid is PBS + 5% skimmed milk powder; the stop solution is 2M H2SO4And (3) solution.
The indirect ELISA antibody detection method for the porcine epidemic diarrhea virus S2 protein is carried out according to the following operations:
coating antigen: diluting the recombinant S2 protein with a coating solution, adding the diluted protein into an ELISA plate for coating, and obtaining a coated ELISA plate with 100 mu L/hole;
washing: discarding the coating solution and washing with a washing solution;
and (3) sealing: adding 250 μ L of sealing solution into each well, sealing at 37 deg.C, discarding the sealing solution, and washing;
incubating the primary antibody: mixing pig serum with the diluent, incubating at 37 deg.C with a volume of 100 μ L/hole, discarding and washing;
incubation of secondary antibody: uniformly mixing the goat anti-pig IgG antibody marked by the HRP with a diluent, incubating at the temperature of 37 ℃ and discarding and washing;
color reading: adding substrate solution into 100 μ L/hole, performing color reaction at room temperature, adding stop solution, and reading OD with enzyme-labeling instrument450The value is obtained.
The recombinant S2 protein was diluted to 8. mu.g/mL with the coating solution, and the dilution of the goat anti-pig IgG antibody labeled with HRP was 1: 4000.
Coating was 4 ℃ overnight plus 37 ℃ for 2 h.
The blocking time was 120 minutes.
The dilution of pig serum was 1:40, and the incubation time was 120 min.
The reaction time for incubating the secondary antibody was 45 minutes.
The color reaction time was 15 minutes.
Aiming at the problem that the detection technology of the Porcine Epidemic Diarrhea Virus (PEDV) antibody is relatively deficient, the inventor combines the S protein to play a key role in the process of mediating virus particles to enter cells and inducing an organism to generate a neutralizing antibody, and designs an indirect ELISA antibody detection kit of the porcine epidemic diarrhea virus S2 protein on the basis of obtaining S2 recombinant protein by expression and purification, wherein the kit comprises a coated enzyme label plate, and the coated enzyme label plate takes the recombinant S2 protein as a coating antigen. Therefore, a corresponding ELISA detection method is established and clinically applied, and a diagnostic tool with practical value is provided for detecting the PEDV antibody. The method for identifying the antibody generated by the porcine epidemic diarrhea virus infection can be established, has higher specificity and sensitivity, is simple to operate, short in time consumption and low in cost, can be used for large-scale detection, and has important significance for prevention, control and purification of the porcine epidemic diarrhea virus infection.
Detailed Description
Establishment of indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein
1. Materials, reagents and apparatus
1.1 Primary reagents
PBS powder: products of the company doctor de;
and (3) skim milk powder: products of the Solarbio corporation;
HRP-labeled goat anti-pig IgG antibody: product of the easthox corporation, usa;
the single-component TMB substrate color developing solution comprises the following components: tiangen products;
96-well enzyme label plate: products of the firm Constar.
Recombinant S2 protein: self-made (coded by a gene base sequence of a sequence table SEQ.ID.No.1 and provided with an amino acid sequence of SEQ.ID.No. 2).
1.2 Main instruments
A water-proof electric heating constant temperature incubator (Shanghai leap forward), an ultraviolet spectrophotometer (Tianpu), an enzyme labeling instrument (Berle) and the like.
1.3 preparation of Indirect ELISA related reagent
1) Coating liquid: 0.05M PH9.6Na was used2CO3-NaHCO3Buffer, weighing Na2CO3 0.159g,NaHCO30.293g, sterile ddH2O to 100mL, and storing at 4 ℃;
2) serum and enzyme-labeled antibody diluent: PBS + 2% skimmed milk powder + 0.05% Tween-20;
3) washing solution: PBS + 0.05% Tween-20;
4) sealing liquid: PBS + 5% skim milk powder;
5) substrate solution: the single-component TMB substrate color developing solution is purchased from Tiangen company;
6) stopping liquid: 2M H2SO4And (3) solution. 11.1mL of concentrated sulfuric acid was slowly added to 80mL of water to make a volume of 100 mL.
2. Methods, procedures and results
2.1 optimization of Indirect ELISA
2.1.1 optimization of optimal coating concentration of recombinant protein and optimal working concentration of Secondary antibody
The recombinant S2 protein was diluted with the coating solution to 32. mu.g/mL, 16. mu.g/mL, 8. mu.g/mL, 4. mu.g/mL, 2. mu.g/mL, 1. mu.g/mL, 0.5. mu.g/mL and 0.25. mu.g/mL of 8 dilutions in order, each dilution coating 1 vertical row of ELISA plate, two. Goat anti-pig IgG HRP-labeled antibody was diluted sequentially at 1:1000, 1:2000, 1:4000, 1:8000, 1:16000, and 1:32000 fold ratios with antibody dilutions in the same horizontal row at 100. mu.L/well to form a matrix. Selection of Positive serum OD450Value and negative serum OD450The antigen concentration and the secondary antibody dilution with the maximum value ratio (P/N value) are used as the optimal antigen coating concentration and the optimal secondary antibody reaction concentration. The results showed that the P/N value was maximal at an antigen coating concentration of 8. mu.g/mL and an enzyme-labeled secondary antibody concentration of 1:4000 (Table 1).
TABLE 1 optimization of optimal antigen coating concentration and optimal dilution factor of secondary antibody
2.1.2 determination of antigen coating conditions
Coating the ELISA plate with the optimal antigen coating concentration obtained in 2.1.1 at a concentration of 100 muL/hole; the experiments were divided into three groups, the first group was coated overnight at 4 ℃; a second group of 4 ℃ coating overnight and 37 ℃ wet box coating for 2 h; the third group was coated for 2h at 37 ℃ wet box. Each group is provided with 3 repeats, and ELISA and enzyme-linked immunosorbent assay are respectively carried out to determine the positive and negativeOD of serum450And calculating the P/N value. Selecting the P/N value as the best antigen coating condition. The results show that 4 ℃ coating overnight plus 37 ℃ coating for 2h is the optimal coating condition, when the P/N value is maximal (Table 2).
TABLE 2 optimization of optimal coating conditions
2.1.3 determination of optimal seal time
The enzyme label plate is coated with the optimal recombinant protein antigen coating concentration and the optimal coating condition, and each well is 100 mu L. The microplate was divided into four groups. Sealing the first group at 37 deg.C for 30min, the second group at 37 deg.C for 60min, the third group at 37 deg.C for 90min, and the fourth group at 37 deg.C for 120 min. After washing, ELISA reaction was performed. Each group was assayed for positive and negative serum OD450And calculating the P/N value to determine the optimal closing time. The results show that blocking at 37 ℃ for 120min is the optimal blocking condition, at which the P/N value is maximal (Table 3).
TABLE 3 determination of optimal seal time
2.1.4 determination of optimal serum dilution and serum incubation time
The enzyme label plate is coated with the optimal recombinant protein antigen coating concentration and the optimal coating condition, and each well is 100 mu L. After blocking, the mixture was divided into three groups. Adding 1:10, 1:20, 1:40, 1:80, 1:160, 1:320 and 1:640 times diluted negative and positive sera into the first group from top to bottom respectively, repeating the steps, and reacting at 37 ℃ for 30 min; adding 1:10, 1:20, 1:40, 1:80, 1:160, 1:320 and 1:640 times diluted negative and positive sera into the second group from top to bottom respectively, repeating the two groups, and reacting at 37 ℃ for 60 min; the third group is added with 1:10, 1:20, 1:40, 1:80, 1:160, 1:320 and 1:640 times diluted negative and positive serum respectively from top to bottom, and the reaction is repeated for 120min at 37 ℃. Respectively carrying out ELISA reaction, and respectively measuring the average O of negative and positive serum of each dilution in each group after the reaction is finishedD450And calculating the P/N value to determine the optimal serum dilution and the optimal serum reaction time. The results show that the P/N values were maximal at 120min incubation with 1:40 fold dilutions of serum (Table 4).
TABLE 4 optimization of optimal serum dilution and action time
2.1.5 determination of optimal Secondary antibody reaction time
The enzyme label plate is coated with the optimal recombinant protein antigen coating concentration and the optimal coating condition, and each well is 100 mu L. After washing, blocking at 37 ℃ for 2h, adding 1:40 diluted negative and positive serum into the reaction vessel, 100. mu.L/well, and reacting at 37 ℃ for 2 h. After washing, HRP-goat anti-porcine IgG antibody diluted 1:4000 was added at 100. mu.L/well. And dividing into four groups, the first group reacting at 37 deg.C for 15min, the second group reacting at 37 deg.C for 30min, the third group reacting at 37 deg.C for 45min, the fourth group reacting at 37 deg.C for 60min, and each group repeating for 3 times. After washing, the color is developed, and the OD of each group of positive and negative serum is determined on an enzyme-linked immunosorbent assay450And calculating the P/N value to determine the optimal reaction time of the secondary antibody. As a result, the maximum P/N value was observed when the secondary antibody reaction time was 45min (Table 5).
TABLE 5 optimization of optimal Secondary antibody reaction time
2.1.6 determination of the color development time of the substrate
The enzyme label plate is coated with the optimal recombinant protein antigen coating concentration and the optimal coating condition, and each well is 100 mu L. After washing, blocking at 37 ℃ for 2h, adding 1:40 diluted negative and positive serum at 100. mu.L/well, and reacting at 37 ℃ for 90 min. After washing, HRP-goat anti-pig IgG antibody diluted 1:4000 times was added thereto at 100. mu.L/well, and the reaction was carried out at 37 ℃ for 45 min. After washing, the mixture was divided into four groups. Adding 100 μ L/well substrate solution into the first group, developing at room temperature for 5min, adding 100 μ L/well substrate solution into the second group, and developing at room temperature for 10 min; adding 100 μ L/well substrate solution into the third group, and developing at room temperature for 15 min; first, theThe four groups were added with 100. mu.L/well substrate solution and developed for 20min at room temperature. Repeating each group for 3 times, adding 50 μ L/well stop solution to stop color development, and measuring OD of positive and negative serum of each group450And calculating the P/N value to determine the optimal substrate color development time. As a result, the P/N value was the largest at 15min of color development (Table 6).
TABLE 6 optimization of optimal substrate development time
2.1.7 optimized Indirect ELISA detection method
In conclusion, the indirect ELISA antibody detection method for the porcine epidemic diarrhea virus S2 protein is carried out according to the following steps:
coating antigen: diluting the recombinant S2 protein to 8 mu g/mL by using a coating solution, adding the diluted recombinant S2 protein into an ELISA plate, coating the ELISA plate at 4 ℃ overnight, coating the ELISA plate at 37 ℃ for 2h, and coating the ELISA plate at 100 mu L/hole to obtain a coated ELISA plate;
washing: discarding the coating solution and washing with a washing solution;
and (3) sealing: adding 250 mu L of sealing liquid into each hole, sealing for 120 minutes at 37 ℃, and removing the sealing liquid for washing;
incubating the primary antibody: mixing pig serum with the diluent at a dilution ratio of 1:40, incubating at 37 deg.C for 120min at 100 μ L/hole, discarding and washing;
incubation of secondary antibody: uniformly mixing the goat anti-pig IgG antibody marked by HRP with the diluent according to the dilution ratio of 1:4000, incubating at the temperature of 37 ℃ for 45 minutes at a concentration of 100 mu L/hole, discarding and washing;
color reading: adding substrate solution into 100 μ L/hole, performing color reaction at room temperature for 15min, adding stop solution, and reading OD with microplate reader450The value is obtained.
2.2 Indirect ELISA Positive and negative cut-off values
Randomly selecting a plurality of fresh pig sera, obtaining 30 pig sera which can not be specifically combined with the recombinant S2 protein through Western-blot analysis, detecting by using established and optimized indirect ELISA, and reading OD of each serum450And calculating the S/P value. S/P valueBetula (sample serum OD)450Value-negative serum OD450Value)/(positive serum OD450Value-negative serum OD450Value). The mean and Standard Deviation (SD) of the S/P values of 30 sera were calculated. When the S/P value of the sample is>-Judging the X +3SD to be positive at any time; when the S/P value of the sample is<The result is judged to be negative when the product is X +2 SD; and when the S/P value of the sample is less than or equal to X +2SD and less than or equal to X +3SD, determining the sample as suspicious.
The mean value X of S/P values of 30 negative sera was calculated to be 0.140 and the standard deviation SD was calculated to be 0.024, thus X +3SD was calculated to be 0.212 and X +2SD was calculated to be 0.188. Therefore, when the S/P value of the serum sample to be detected is greater than 0.212, the serum sample is judged to be positive; judging the sample to be detected as negative when the S/P value of the sample is less than 0.188; and when the S/P value of the serum sample to be detected is less than or equal to 0.188 and less than or equal to 0.212, the serum sample is judged to be suspicious.
2.3 specificity test
The enzyme-labeled hole is coated with the purified recombinant protein PEDV S2 protein, and then classical swine fever virus standard positive serum, porcine reproductive and respiratory syndrome virus standard positive serum, porcine circovirus standard positive serum, porcine foot-and-mouth disease virus standard positive serum, porcine pseudorabies virus standard positive serum and porcine delta coronavirus standard positive serum are detected according to the ELSIA method established and optimized in the foregoing, and meanwhile, a PEDV negative positive serum control is set to judge whether the PEDV S2 protein indirect ELISA antibody detection method established in the experiment has cross reaction with antibodies of other pathogens. The results show that the S/P values of the classical swine fever virus standard positive serum, the porcine reproductive and respiratory syndrome virus standard positive serum, the porcine circovirus standard positive serum, the foot-and-mouth disease virus standard positive serum, the porcine pseudorabies virus standard positive serum and the porcine delta coronavirus standard positive serum are all less than 0.188 (Table 7), so that the PEDV S2 protein indirect ELISA antibody detection method established in the research has good specificity.
TABLE 7 Indirect ELISA antibody specificity test results for PEDV S2 protein
2.4 repeatability test
Three batches of PEDV S2 protein were coated on days 1, 3, and 5, respectively, and negative and positive sera were tested by ELISA on day 6, with 5 replicates in a batch, for OD determination450And calculating the average value, the standard deviation and the coefficient of variation.
2.4.1 in-batch repeatability: and calculating the variation coefficient among 5 repeats in each batch, and determining the repeatability in the batch according to the magnitude of the variation coefficient. OD of in-batch Positive sera450The coefficient of variation of the value is between 1.4 and 3.0 percent, and the OD of the negative serum450The coefficient of variation of the values was between 3.6% and 4.9% (table 8).
2.4.2 batch to batch repeatability: and calculating the variation coefficient among the three batches, and determining the repeatability among the batches according to the variation coefficient. OD of batch Positive sera450The value variation coefficient was 1.1%, OD of negative serum450The value variation coefficient was 2.6% (Table 8).
TABLE 8 result of repetitive test of indirect ELISA antibody with PEDV S2 protein
The results of the in-batch and inter-batch tests show that the ELISA detection method established by the research has better repeatability.
2.5 sensitivity test
3 parts of PEDV positive serum are diluted in a ratio of 1:40, and are detected by an established ELISA kit, and a negative positive control is set. Determination of OD450And calculating S/P value, and analyzing the sensitivity. As a result: OD of negative and positive controls in this experiment450The values were 0.086 and 1.085, respectively, and the S/P values at each dilution were calculated for 3 positive sera, respectively. The results showed that 2 positive sera were negative at 1:640 (S/P values)<0.188), 1 part of positive serum becomes negative when the ratio of the positive serum to the negative serum is 1:1280, which indicates that the kit has better sensitivity, and the results are shown in a table 9.
TABLE 9 Indirect ELISA antibody sensitivity test results for PEDV S2 protein
2.6 preliminary application of Indirect ELISA antibody detection method of PEDV S2 protein
The indirect ELISA antibody of PEDV S2 protein established in the research is used for detecting 385 total swine herd serum samples in different stages in Guangxi area, the positive rate is calculated, and the PEDV antibody level of the swine herd in each stage in the Guangxi area is analyzed, and the result is shown in Table 10. From the detection results, the total sample positive rate is 76.36%, the positive rates at different stages are greatly different, the highest positive rate of the sows is 86.36%, and the lowest positive rate of the nursery pigs is 53.57%.
TABLE 10 results of clinical serum PEDV antibody detection
Sequence listing
<110> Guangxi Zhuang nationality autonomous region veterinary research institute
<120> indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1524
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
tgtgccacat atgtttgtaa tggtaactct cgttgtaaac aattactcac ccagtacact 60
gcagcatgta agaccataga gtcagcatta caactcagcg ctaggcttga gtctgttgaa 120
gttaactcta tgcttactat ttctgaagag gctctacagt tagccaccat tagttcgttt 180
aatggtgatg gatataattt tactaatgtg ctgggtgttt ctgtgtatga tcctgcaagt 240
ggcagggtgg tacaaaaaag gtcttttatt gaagacctgc tttttaataa agtggttact 300
aatggccttg gtactgttga tgaagactat aagcgctgtt ctaatggtcg ctctgtggca 360
gatctagtct gtgcacagta ttactctggt gtcatggtac tacctggtgt tgttgacgct 420
gagaagcttc acatgtatag tgcgtctctc atcggtggta tggtgctagg aggttttact 480
tctgcagcgg cattgccttt tagctatgct gttcaagcta gactcaatta tcttgctcta 540
cagacggatg ttctacagcg gaaccaacaa ttgcttgctg agtcttttaa ctctgctatt 600
ggtaatataa cttcagcctt tgagagtgtt aaagaggcta ttagtcaaac ttccaagggt 660
ttgaacactg tggctcatgc gcttactaag gttcaagagg ttgttaactc gcagggtgca 720
gctttgactc aacttaccgt acagctgcaa cacaatttcc aagccatttc tagttctatt 780
gatgacattt actctcgact ggacattctt tcagccgatg ttcaggttga ccgtctcatc 840
accggcagat tatcagcact taatgctttt gttgctcaaa ccctcactaa gtatactgag 900
gttcaggcta gcaggaagct agcacagcaa aaggttaatg agtgcgttaa atcgcaatct 960
cagcgttatg gtttttgtgg tggtgatggc gagcacattt tctctctggt acaggcagca 1020
cctcagggcc tgctgttttt acatacagta cttgtaccgg gtgactttgt agatgttatt 1080
gccatcgctg gcttatgcgt taacgatgaa attgccttga ctctacgtga gcctggctta 1140
gtcttgttta cgcatgaact tcaaaatcat actgcgacgg aatattttgt ttcatcgcga 1200
cgtatgtttg aacctagaaa acctaccgtt agtgattttg ttcaaattga gagttgtgtg 1260
gtcacctatg tcaatttgac tagagaccaa ctaccagatg taatcccaga ttacatcgat 1320
gttaacaaaa cacttgatga gattttagct tctctgccca atagaactgg tccaagtctt 1380
cctttagatg tttttaatgc cacttatctt aatctcactg gtgaaattgc agatttagag 1440
cagcgttcag agtctctccg taatactaca gaggagctcc aaagtcttat atataatatc 1500
aacaacacac tagttgacct tgag 1524
<210> 2
<211> 508
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Cys Ala Thr Tyr Val Cys Asn Gly Asn Ser Arg Cys Lys Gln Leu Leu
1 5 10 15
Thr Gln Tyr Thr Ala Ala Cys Lys Thr Ile Glu Ser Ala Leu Gln Leu
20 25 30
Ser Ala Arg Leu Glu Ser Val Glu Val Asn Ser Met Leu Thr Ile Ser
35 40 45
Glu Glu Ala Leu Gln Leu Ala Thr Ile Ser Ser Phe Asn Gly Asp Gly
50 55 60
Tyr Asn Phe Thr Asn Val Leu Gly Val Ser Val Tyr Asp Pro Ala Ser
65 70 75 80
Gly Arg Val Val Gln Lys Arg Ser Phe Ile Glu Asp Leu Leu Phe Asn
85 90 95
Lys Val Val Thr Asn Gly Leu Gly Thr Val Asp Glu Asp Tyr Lys Arg
100 105 110
Cys Ser Asn Gly Arg Ser Val Ala Asp Leu Val Cys Ala Gln Tyr Tyr
115 120 125
Ser Gly Val Met Val Leu Pro Gly Val Val Asp Ala Glu Lys Leu His
130 135 140
Met Tyr Ser Ala Ser Leu Ile Gly Gly Met Val Leu Gly Gly Phe Thr
145 150 155 160
Ser Ala Ala Ala Leu Pro Phe Ser Tyr Ala Val Gln Ala Arg Leu Asn
165 170 175
Tyr Leu Ala Leu Gln Thr Asp Val Leu Gln Arg Asn Gln Gln Leu Leu
180 185 190
Ala Glu Ser Phe Asn Ser Ala Ile Gly Asn Ile Thr Ser Ala Phe Glu
195 200 205
Ser Val Lys Glu Ala Ile Ser Gln Thr Ser Lys Gly Leu Asn Thr Val
210 215 220
Ala His Ala Leu Thr Lys Val Gln Glu Val Val Asn Ser Gln Gly Ala
225 230 235 240
Ala Leu Thr Gln Leu Thr Val Gln Leu Gln His Asn Phe Gln Ala Ile
245 250 255
Ser Ser Ser Ile Asp Asp Ile Tyr Ser Arg Leu Asp Ile Leu Ser Ala
260 265 270
Asp Val Gln Val Asp Arg Leu Ile Thr Gly Arg Leu Ser Ala Leu Asn
275 280 285
Ala Phe Val Ala Gln Thr Leu Thr Lys Tyr Thr Glu Val Gln Ala Ser
290 295 300
Arg Lys Leu Ala Gln Gln Lys Val Asn Glu Cys Val Lys Ser Gln Ser
305 310 315 320
Gln Arg Tyr Gly Phe Cys Gly Gly Asp Gly Glu His Ile Phe Ser Leu
325 330 335
Val Gln Ala Ala Pro Gln Gly Leu Leu Phe Leu His Thr Val Leu Val
340 345 350
Pro Gly Asp Phe Val Asp Val Ile Ala Ile Ala Gly Leu Cys Val Asn
355 360 365
Asp Glu Ile Ala Leu Thr Leu Arg Glu Pro Gly Leu Val Leu Phe Thr
370 375 380
His Glu Leu Gln Asn His Thr Ala Thr Glu Tyr Phe Val Ser Ser Arg
385 390 395 400
Arg Met Phe Glu Pro Arg Lys Pro Thr Val Ser Asp Phe Val Gln Ile
405 410 415
Glu Ser Cys Val Val Thr Tyr Val Asn Leu Thr Arg Asp Gln Leu Pro
420 425 430
Asp Val Ile Pro Asp Tyr Ile Asp Val Asn Lys Thr Leu Asp Glu Ile
435 440 445
Leu Ala Ser Leu Pro Asn Arg Thr Gly Pro Ser Leu Pro Leu Asp Val
450 455 460
Phe Asn Ala Thr Tyr Leu Asn Leu Thr Gly Glu Ile Ala Asp Leu Glu
465 470 475 480
Gln Arg Ser Glu Ser Leu Arg Asn Thr Thr Glu Glu Leu Gln Ser Leu
485 490 495
Ile Tyr Asn Ile Asn Asn Thr Leu Val Asp Leu Glu
500 505
Claims (9)
1. The indirect ELISA antibody detection kit for the porcine epidemic diarrhea virus S2 protein comprises a coated ELISA plate, and is characterized in that: the coated enzyme label plate takes recombinant S2 protein as a coating antigen; the recombinant S2 protein is encoded by a gene base sequence of a sequence table SEQ ID No.1 or is an amino acid sequence of SEQ ID No. 2.
2. The ELISA antibody detection kit of claim 1, characterized by further comprising a negative serum, a positive serum, a goat anti-pig IgG antibody labeled with HRP, a washing solution, a diluent, a coating solution, a blocking solution, a substrate solution, a stop solution; the washing solution is PBS + 0.05% Tween-20; the diluent is PBS + 2% skimmed milk powder + 0.05% Tween-20; the coating solution is 0.05M pH9.6Na2CO3-NaHCO3A buffer solution; the substrate solution is a single-component TMB substrate color development solution; the confining liquid is PBS + 5% skimmed milk powder; the stop solution is 2M H2SO4And (3) solution.
3. An indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein is characterized by comprising the following steps: coating antigen: diluting the recombinant S2 protein with a coating solution, adding the diluted protein into an ELISA plate for coating, and obtaining a coated ELISA plate with 100 mu L/hole; the recombinant S2 protein is encoded by a gene base sequence of a sequence table SEQ ID No.1 or is an amino acid sequence of SEQ ID No. 2;
washing: discarding the coating solution and washing with a washing solution;
and (3) sealing: adding 250 μ L of sealing solution into each well, sealing at 37 deg.C, discarding the sealing solution, and washing;
incubating the primary antibody: mixing pig serum with the diluent, incubating at 37 deg.C with 100 μ L/hole, discarding and washing;
incubation of secondary antibody: uniformly mixing the goat anti-pig IgG antibody marked by the HRP with a diluent, incubating at the temperature of 37 ℃ and discarding and washing;
color reading: adding substrate solution into 100 μ L/hole, performing color reaction at room temperature, adding stop solution, and reading OD with enzyme-labeling instrument450The value is obtained.
4. The ELISA antibody detection method of claim 3, wherein: the recombinant S2 protein was diluted to 8. mu.g/mL with coating solution, and the dilution of the HRP-labeled goat anti-pig IgG antibody was 1: 4000.
5. The ELISA antibody detection method of claim 4, wherein: the coating was 4 ℃ overnight plus 37 ℃ for 2 h.
6. The ELISA antibody detection method of claim 5, wherein: the blocking time was 120 minutes.
7. The ELISA antibody detection method of claim 6, wherein: the dilution of the pig serum is 1:40, and the incubation time is 120 min.
8. The ELISA antibody detection method of claim 7, wherein: the reaction time for the incubation of the secondary antibody was 45 minutes.
9. The ELISA antibody detection method of claim 8, wherein: the color reaction time was 15 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910140122.3A CN109884314B (en) | 2019-02-26 | 2019-02-26 | Indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910140122.3A CN109884314B (en) | 2019-02-26 | 2019-02-26 | Indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109884314A CN109884314A (en) | 2019-06-14 |
CN109884314B true CN109884314B (en) | 2022-06-03 |
Family
ID=66929384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910140122.3A Expired - Fee Related CN109884314B (en) | 2019-02-26 | 2019-02-26 | Indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109884314B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112415207B (en) * | 2020-10-27 | 2022-04-12 | 中国农业科学院兰州兽医研究所 | IgA antibody ELISA detection kit based on anti-porcine epidemic diarrhea virus variant strain recombinant S2 protein |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104155454A (en) * | 2014-08-20 | 2014-11-19 | 浙江省农业科学院 | ELISA kit for detecting porcine epidemic diarrhea virus pandemic strain antibody |
CN104292311A (en) * | 2014-09-05 | 2015-01-21 | 中山大学 | Antigen for detecting porcine epidemic diarrhea virus neutralizing antibody, and preparation method and application thereof |
CN106367400A (en) * | 2016-09-18 | 2017-02-01 | 广西壮族自治区兽医研究所 | Variation strain for porcine epidemic diarrhea virus and isolated culturing method and application thereof |
CN106950369A (en) * | 2017-03-15 | 2017-07-14 | 华南农业大学 | A kind of pig epidemic diarrhea novel antibodies ELISA detection kit |
CN206756849U (en) * | 2017-05-05 | 2017-12-15 | 浙江海隆生物科技有限公司 | The indirect ELISA testing kit of Porcine epidemic diarrhea virus N protein and S protein antibody |
-
2019
- 2019-02-26 CN CN201910140122.3A patent/CN109884314B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104155454A (en) * | 2014-08-20 | 2014-11-19 | 浙江省农业科学院 | ELISA kit for detecting porcine epidemic diarrhea virus pandemic strain antibody |
CN104292311A (en) * | 2014-09-05 | 2015-01-21 | 中山大学 | Antigen for detecting porcine epidemic diarrhea virus neutralizing antibody, and preparation method and application thereof |
CN106367400A (en) * | 2016-09-18 | 2017-02-01 | 广西壮族自治区兽医研究所 | Variation strain for porcine epidemic diarrhea virus and isolated culturing method and application thereof |
CN106950369A (en) * | 2017-03-15 | 2017-07-14 | 华南农业大学 | A kind of pig epidemic diarrhea novel antibodies ELISA detection kit |
CN206756849U (en) * | 2017-05-05 | 2017-12-15 | 浙江海隆生物科技有限公司 | The indirect ELISA testing kit of Porcine epidemic diarrhea virus N protein and S protein antibody |
Non-Patent Citations (1)
Title |
---|
The S2 glycoprotein subunit of porcine epidemic diarrhea virus contains immunodominant neutralizing epitopes;Faten A.Okda等;《Virology》;20170930;第509卷;第185-194页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109884314A (en) | 2019-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109655621B (en) | Indirect ELISA antibody detection method for swine T-type coronavirus N protein and kit thereof | |
CN111072774B (en) | anti-African swine fever P30 protein single-domain antibody and ELISA kit for detecting African swine fever virus | |
CN102928585B (en) | Mycoplasma hyopneumoniae antibody detection kit and manufacture method thereof | |
CN105527442B (en) | A kind of hog cholera antibody detecting system and preparation method thereof | |
Liu et al. | Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips | |
Lang et al. | Development of a peptide ELISA for discrimination between serological responses to equine herpesvirus type 1 and 4 | |
CN111381032A (en) | Indirect ELISA detection method for detecting porcine epidemic diarrhea virus antibody and kit thereof | |
CN113336845B (en) | Porcine single B cell antibody of PRRSV nucleocapsid protein and competitive ELISA antibody detection kit | |
CN113265006B (en) | Fusion protein 3AN for capturing PRRSV nucleocapsid protein antibody and application thereof | |
CN111929433A (en) | African swine fever virus antibody ELISA detection kit and preparation method thereof | |
CN102731615A (en) | Detection reagent and detection method for PRRSV | |
CN112213497B (en) | polypeptide-ELISA kit for detecting novel coronavirus S protein unique antibody | |
CN111551750B (en) | Indirect ELISA (enzyme-linked immunosorbent assay) detection kit for porcine astrovirus | |
CN111474346B (en) | Porcine epidemic diarrhea virus IgA and IgG antibody detection kit, and preparation method and application thereof | |
Li et al. | Development and partial validation of a recombinant E2-based indirect ELISA for detection of specific IgM antibody responses against classical swine fever virus | |
CN106518989B (en) | Polypeptide for detecting porcine Delta coronavirus antibody, preparation method and application thereof | |
CN109884314B (en) | Indirect ELISA antibody detection method for porcine epidemic diarrhea virus S2 protein and kit thereof | |
CN102854317A (en) | EV71 (human enterovirus 71) antigen enzyme-linked reaction detection kit and its preparation method | |
CN109239341A (en) | A kind of indirect ELISA reagent kit of ox Mannheimia haemolytica antibody test and its application | |
CN107576791A (en) | One boar lawsonia intracellularis ELISA detection kit | |
CN106866798B (en) | Subgroup J avian leukosis virus specific epitope, fusion protein, specific antibody and application thereof | |
CN109187952A (en) | One boar atypia pestivirus ELISA antibody assay kit | |
CN104165998B (en) | PRRSV genetic marker vaccine strain ELISA differential diagnosis kit and methods and applications | |
CN107064502B (en) | A kind of multiple ELISA detection kit of pig virus infectious disease serum IgG antibody and its detection method | |
Shapouri et al. | A novel competitive ELISA for detection of antibodies against bovine viral diarrhea virus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220603 |
|
CF01 | Termination of patent right due to non-payment of annual fee |